Aptorum Group stock falls after $2 million direct offering

Published 10/10/2025, 15:08
© Reuters.

Investing.com -- Aptorum Group Limited (NASDAQ:APM) stock tumbled 23% following the announcement of a registered direct offering and concurrent private placement to raise $2 million.

The clinical stage biopharmaceutical company revealed it has entered into definitive agreements to sell 1,000,000 Class A ordinary shares at $2.00 per share. In a parallel private placement, Aptorum will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per share, exercisable upon issuance with a 24-month expiration period.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering, which is expected to close around October 14, 2025, subject to customary closing conditions.

The company plans to use the proceeds to fund expenses related to its previously announced merger agreement with DiamiR Biosciences Corp. and for general working capital of both companies pending the merger’s anticipated closing. The merger remains contingent on several factors, including approval by Aptorum’s shareholders.

If the unregistered warrants are fully exercised on a cash basis, Aptorum could receive additional gross proceeds of $4 million, though the company noted there is no assurance that any warrants will be exercised.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.